[Risk stratification for thromboembolism and antithrombotic prophylaxis in atrial fibrillation]

Area of Science:

• Cardiology
• Pharmacology

Context:

• Atrial fibrillation (AF) poses a significant risk of stroke and systemic embolism.
• Warfarin effectively reduces thromboembolic risk in AF patients, but its use is limited by suboptimal anticoagulation quality and frequent discontinuations.
• Risk stratification scores like CHA2DS2-VASc improve accuracy in identifying patients who would benefit from oral anticoagulant therapy (OAT).

Purpose:

• To review the current landscape of oral anticoagulant therapy (OAT) for atrial fibrillation (AF).
• To highlight the limitations of warfarin and the growing clinical expectation for novel oral anticoagulants (NOACs).

Summary:

• Atrial fibrillation (AF) is linked to a high risk of stroke (4.5%/year).
• While warfarin is effective, its clinical use is hampered by issues like underuse and poor anticoagulation control.
• Newer agents, including direct thrombin inhibitors (e.g., dabigatran) and factor Xa inhibitors (e.g., rivaroxaban, apixaban), demonstrate non-inferiority to warfarin with improved safety profiles, presenting a promising therapeutic alternative.

Impact:

• The advent of NOACs offers a potentially safer and more effective therapeutic alternative for AF patients requiring anticoagulation.
• Expanded indications for OAT in AF, guided by risk scores, underscore the need for accessible and well-tolerated treatment options.
• Addressing the challenges of OAT underuse and suboptimal control is crucial for improving stroke prevention in the AF population.